Personalised healthcare, the targeting of treatments to patients with specific genetic profiles, seems to have finally come of age. An example of its emergence into mainstream healthcare is Dutch company Qiagen's recent decision to invest $130m in UK-based molecular diagnostics company DxS, ...
Please Login to read the full article.
